Telix Pharmaceuticals Limited or ACADIA Pharmaceuticals Inc.: Who Leads in Yearly Revenue?

ACADIA vs. Telix: A Decade of Revenue Growth

__timestampACADIA Pharmaceuticals Inc.Telix Pharmaceuticals Limited
Wednesday, January 1, 201412000028336824
Thursday, January 1, 20156100032319194
Friday, January 1, 20161733100029404631
Sunday, January 1, 201712490100031769230
Monday, January 1, 201822380700020439380
Tuesday, January 1, 201933907600024186536
Wednesday, January 1, 20204417550004680000
Friday, January 1, 20214841450004898000
Saturday, January 1, 2022517235000155984000
Sunday, January 1, 2023726437000496659000
Loading chart...

Infusing magic into the data realm

A Revenue Race: ACADIA vs. Telix Pharmaceuticals

In the competitive landscape of pharmaceuticals, revenue growth is a key indicator of success. Over the past decade, ACADIA Pharmaceuticals Inc. and Telix Pharmaceuticals Limited have been vying for dominance. ACADIA has shown a remarkable upward trajectory, with its revenue surging from a modest $61,000 in 2015 to an impressive $726 million by 2023. This represents a staggering growth of over 11,900% in just eight years.

Meanwhile, Telix Pharmaceuticals has also made significant strides, particularly in recent years. From 2014 to 2023, Telix's revenue increased from approximately $28 million to nearly $497 million, marking a growth of over 1,670%. Notably, Telix's revenue saw a dramatic leap in 2022, indicating a promising future.

As these two companies continue to innovate and expand, the pharmaceutical industry watches closely to see who will lead the charge in the coming years.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025